FindTrial
Sign In

To investigate the relationship between gene polymorphism of GLP-1 signaling pathway and pharmacotherapy phenotype, and to explore the precise treatment of type 2 diabetes mellitus of GLP-1 RAs with SNP chip technology.

To investigate the relationship between gene polymorphism of GLP-1 signaling pathway and pharmacotherapy phenotype, and to explore the precise treatment of type 2 diabetes mellitus of GLP-1 RAs with SNP chip technology.

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024959
Enrollment
Unknown
Registered
2019-08-05
Start date
2019-08-04
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Case series:GLP-1RAs

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who first diagnose for type 2 diabetes (WHO 1999 diagnostic criteria) and use GLP-1 receptor agonists; 2. patients with GLP-1RAs added after three months of stable hypoglycemic schedule.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who are allergic to this type of drugs; 3. Patients with gastrointestinal diseases or who have recently taken drugs that cause gastrointestinal disfunction; 4. Patients with severely impaired liver and kidney function; 5. Type 1 diabetes; 6. Patients with the history of pancreatic and thyroid disorders.

Design outcomes

Primary

MeasureTime frame
genotye;body weight;blood glucose;Gastrointestinal adverse reactions;insulin;glucagon;GLP-1;—

Secondary

MeasureTime frame
Biochemical examination;—

Countries

China

Contacts

Public ContactDongfang Liu

The Second Affiliated Hospital of Chongqing Medical University

ldf023023@qq.com+86 18623407751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026